Overview

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate
Brimonidine Tartrate, Timolol Maleate Drug Combination
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Criteria
Inclusion Criteria:

- Open-angle glaucoma or ocular hypertension in at least one eye that is not responsive
to topical beta blockers

- No anticipated wearing of contact lenses during study

Exclusion Criteria:

- Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular
infections or severe dry eye)

- Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months

- Required regular use of other ocular medications except for occasional use of
artificial tears